Expanding the Understanding of Geographic Atrophy (Online CME Monograph)
Activity Description and Purpose
Geographic atrophy is a deleterious disease that leads to visual function loss and affects the ability to perform tasks of daily living. Although nonpharmacologic options are available to aid those with vision impairment, no US Food and Drug Administration–approved therapies exist for geographic atrophy. This educational activity is intended to increase clinician awareness of geographic atrophy, with the ultimate goal of positively impacting their clinical practice and patient care. Experts will provide information on the epidemiology, pathophysiology, burden of disease, current landscape of care, and emerging treatments for geographic atrophy. The desired results of this activity are for retina specialists and other ophthalmologists to enhance patient communication in order to raise awareness and understanding and to help reduce the burden of geographic atrophy.
This educational activity is intended for retina specialists and other ophthalmologists.
After completing this activity, participants will be better able to:
- Recognize factors that influence the epidemiology of geographic atrophy
- Recommend strategies to assist patients in managing the burden of geographic atrophy
- Describe the pathophysiology of geographic atrophy
- Incorporate education on geographic atrophy regularly into patient encounters
|Michael Singer, MD (Chair)|
Clinical Professor of Ophthalmology
University of Texas Health Science Center
Director of Clinical Research
Medical Center Ophthalmology Associates
San Antonio, Texas
|Arshad M. Khanani, MD, MA, FASRS|
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada, Reno School of Medicine
|Judy E. Kim, MD, FARVO, FASRS|
Professor, Ophthalmology and Visual Sciences
Professor, Graduate School of Biomedical Sciences
Director, Teleophthalmology and Research
Medical College of Wisconsin
|Rishi P. Singh, MD|
Staff Physician and President
Cleveland Clinic Martin Hospitals
Cleveland Clinic Florida
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Arshad M. Khanani, MD, MA, is a consultant for Alimera Sciences, Allergan, Apellis Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch & Lomb Incorporated, Broadwing Bio, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Cholgene Therapeutics Inc, F. Hoffmann-La Roche Ltd, 4DMT, Gemini Therapeutics, Genentech, Inc, Graybug, Inc, Gyroscope, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kato Pharmaceuticals, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Oculis, Opthea, Oxurion NV, PolyPhotonix, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Retrotope Inc, Thea Pharmaceuticals Limited, and Unity Biotechnology; is on the speakers bureau for Allergan, Genentech, Inc, and Novartis Pharmaceuticals Corporation; is a contracted researcher for Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, 4DMT, Gemini Therapeutics, Genentech, Inc, Gyroscope, Iveric Bio, Inc, Kodiak Sciences Inc, NGM Bio, Novartis Pharmaceuticals Corporation, Oculis, Opthea, Oxurion NV, Regenxbio Inc, and Unity Biotechnology; and has individual stocks or stock options in Aviceda Therapeutics, PolyPhotonix, Recens Medical, Inc, and Retrotope Inc.
Judy E. Kim, MD, is an advisory board member of Adverum, Alimera Sciences, Allergan, Astellas Pharma Inc, Bausch & Lomb Incorporated, Clearside Biomedical, Inc, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Genentech, Inc, Notal Vision, Inc, Novartis Pharmaceuticals Corporation, Outlook Therapeutics, Inc, and Regeneron Pharmaceuticals, Inc; and was formerly a contracted researcher for Notal Vision, Inc, within the past 2 years.
Michael Singer, MD, is a consultant for Allergan, EyePoint Pharmaceuticals, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc; and is on the speakers bureau for Allergan, Apellis Pharmaceuticals, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc.
Rishi P. Singh, MD, is a consultant for Alcon, AsclepiX Therapeutics, Bausch & Lomb Incorporated, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gyroscope, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Zeiss.
Danny Mammo, MD, formerly served as an advisory board member for Alimera Sciences, EyePoint Pharmaceuticals, and Genentech, Inc, within the past 2 years, but those relationships have ended.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Iveric Bio, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Iveric Bio, Inc.
©2022 MedEdicus LLC. 273
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation